Additionally, peptide seq-1 targets HepG2 human hepatocellular carcinoma cells (HepG2 cells) to negatively regulate the TGF-β signaling pathway, reducing the synthesis of ECM and alleviating the imbalance of ECM-remodeling-related enzymes MMP-2 and TIMP-2. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.